

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: John K. Pratt, et al.  
Serial No: 10/699,513  
Filed: October 23, 2003  
Title: Anti-Infective Agents  
Confirmation No: 7849  
Group Art Unit: 1616  
Examiner: Alton Nathaniel Pryor  
Attorney Ref: 6998USO2

January 16, 2009

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir/Madam:

To comply with 37 C.F.R. §1.97 and §198, Applicants submit the enclosed supplemental Form PTO-1449 and copies of all documents listed on that form with the exception of any cited U.S. patents and U.S. patent application publications.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of this application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider a listed document to be sufficiently pertinent to use in a rejection or to be prior art for any reason. Applicants make this request so that each document becomes cited on the face of a patent issuing from this application.

Applicants submit this Supplemental Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 C.F.R. §1.65, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 C.F.R. §1.104(a) and §1.106(b) and, in the course of such search, will review for relevance every document listed on the enclosed Form PTO-1449 even if not initialed.

As to reference C11, please see the English abstracts and reaction schemes as well as Example 162A from the application.

As to reference C24, please see the English abstracts and reaction schemes as well as Example 311A from the application.

\* \* \* \* \*

Applicants authorize the Commissioner to charge \$180 for the filing of this Supplemental Information Disclosure Statement to Deposit Account No. 01-0025. Applicants believe that they do not owe any other fee(s) for this filing. If, however, Applicants do owe such fee(s), the Commissioner is hereby authorized to charge those fee(s) to Deposit Account No. 01-0025. In addition, if there is ever any fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. 01-0025.

Respectfully submitted,  
Douglas K. Hutchinson et al.

/Lydia N. Nenow/  
Lydia N. Nenow, PTO Reg. No. 52,530  
Abbott Laboratories  
Dept. 0377, Bldg. AP6A-1  
100 Abbott Park Road  
Abbott Park, IL 60064  
(847) 938-0389 (tel)  
(847) 938-2623 (fax)

**CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence is being electronically filed with the U.S. Patent and Trademark Office on **January 16, 2009**.

/Lydia N. Nenow/  
Lydia N. Nenow, PTO Reg. No. 52,530